Whole-exome sequencing identifies the first French MODY 6 family with a new mutation in the NEUROD1 gene.


Journal

Diabetes & metabolism
ISSN: 1878-1780
Titre abrégé: Diabetes Metab
Pays: France
ID NLM: 9607599

Informations de publication

Date de publication:
10 2020
Historique:
received: 01 10 2019
revised: 05 02 2020
accepted: 04 03 2020
pubmed: 19 3 2020
medline: 3 11 2021
entrez: 19 3 2020
Statut: ppublish

Résumé

The aim of the present study was to identify the affected gene in a French family with maturity-onset diabetes of the young (MODY) using whole-exome sequencing (WES). WES was performed in one patient with MODY, and candidate variants were confirmed in members of the immediate family by Sanger sequencing. In the proband, a new heterozygous missense mutation (c.340A>C) was identified in the NEUROD1 gene by WES analysis and confirmed by Sanger sequencing. Additional Sanger sequencing of the proband's sister and mother revealed the same heterozygous mutation. The proband and his sister displayed typical clinical characteristics of MODY, while their mother had the same typical MODY features except for later onset. When clinical and biological profiles were established for all three patients, the severity of diabetes-related complications varied substantially from one family member to another. A novel missense mutation found in NEUROD1 was associated with MODY 6 features in a single French family.

Identifiants

pubmed: 32184107
pii: S1262-3636(20)30031-8
doi: 10.1016/j.diabet.2020.03.001
pii:
doi:

Substances chimiques

Basic Helix-Loop-Helix Transcription Factors 0
Hypoglycemic Agents 0
Insulin 0
NEUROD1 protein, human 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

400-402

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

B Bouillet (B)

Department of Endocrinology, Diabetes and Metabolic Disorders, Dijon University Hospital, hôpital François Mitterrand, BP 77908, 21079 Dijon, France; Inserm Unit, LNC-UMR 1231, University of Burgundy, Dijon, France. Electronic address: benjamin.bouillet@chu-dijon.fr.

E Crevisy (E)

Department of Endocrinology, Diabetes and Metabolic Disorders, Dijon University Hospital, hôpital François Mitterrand, BP 77908, 21079 Dijon, France.

S Baillot-Rudoni (S)

Department of Endocrinology, Diabetes and Metabolic Disorders, Dijon University Hospital, hôpital François Mitterrand, BP 77908, 21079 Dijon, France.

D Gallegarine (D)

Genetics Department, Dijon University Hospital, Dijon, France.

T Jouan (T)

Genetics Department, Dijon University Hospital, Dijon, France.

Y Duffourd (Y)

Genetics Department, Dijon University Hospital, Dijon, France.

J M Petit (JM)

Department of Endocrinology, Diabetes and Metabolic Disorders, Dijon University Hospital, hôpital François Mitterrand, BP 77908, 21079 Dijon, France; Inserm Unit, LNC-UMR 1231, University of Burgundy, Dijon, France.

B Vergès (B)

Department of Endocrinology, Diabetes and Metabolic Disorders, Dijon University Hospital, hôpital François Mitterrand, BP 77908, 21079 Dijon, France; Inserm Unit, LNC-UMR 1231, University of Burgundy, Dijon, France.

P Callier (P)

Genetics Department, Dijon University Hospital, Dijon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH